Perceptive Advisors LLC 13F holdings, Q2 2025
Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →
Perceptive Advisors LLC disclosed 82 US equity positions worth $2.7bn in its Q2 2025 13F filing. The largest position was VRNA at 19.5% of the reported book, followed by ASND and ACLXGBX. Against the Q1 2025 filing, it opened 7 new positions, added to 10 and reduced 24 among the top 50 holdings.
What did Perceptive Advisors LLC own in Q2 2025? Top 50 positions
| # | Stock | Sector | Weight | Value | Shares | Δ shares | vs Q1 2025 |
|---|---|---|---|---|---|---|---|
| 1 | VRNA VERONA PHARMA PLC | 19.5% | $520.9m | 5,507,591 | -16% | reduced | |
| 2 | ASND ASCENDIS PHARMA A/S | Healthcare | 6.2% | $166.4m | 963,886 | – | new |
| 3 | ACLXGBX ARCELLX INC | 6.1% | $163.2m | 2,478,000 | -15% | reduced | |
| 4 | RYTM RHYTHM PHARMACEUTICALS INC | Healthcare | 5.7% | $152.8m | 2,418,299 | -5% | reduced |
| 5 | NUVALENT INC | 3.9% | $104.9m | 1,375,180 | -16% | reduced | |
| 6 | AORT ARTIVION INC | Healthcare | 3.3% | $86.9m | 2,793,703 | 0% | held |
| 7 | MGTX MEIRAGTX HLDGS PLC | 3.1% | $82.2m | 12,626,103 | 0% | held | |
| 8 | INSM INSMED INC | Healthcare | 2.5% | $65.4m | 650,252 | 28% | added |
| 9 | EWTX EDGEWISE THERAPEUTICS INC | 2.3% | $60.8m | 4,639,949 | -29% | reduced | |
| 10 | PTGX PROTAGONIST THERAPEUTICS INC | Healthcare | 2.2% | $59.4m | 1,074,448 | -2% | reduced |
| 11 | SLDB SOLID BIOSCIENCES INC | Healthcare | 2.2% | $58.0m | 11,906,646 | 0% | held |
| 12 | APGE APOGEE THERAPEUTICS INC | Healthcare | 1.9% | $51.3m | 1,182,148 | 5% | added |
| 13 | AMLX AMYLYX PHARMACEUTICALS INC | Healthcare | 1.9% | $50.7m | 7,902,365 | 0% | held |
| 14 | IMTX IMMATICS N.V | Healthcare | 1.9% | $50.5m | 9,383,456 | 0% | held |
| 15 | AKERO THERAPEUTICS INC | 1.8% | $48.9m | 915,887 | 16% | added | |
| 16 | OMDA OMADA HEALTH INC | Healthcare | 1.7% | $44.4m | 2,426,330 | – | new |
| 17 | AM6 AMICUS THERAPEUTICS INC | 1.6% | $42.5m | 7,412,830 | -65% | reduced | |
| 18 | ROIV ROIVANT SCIENCES LTD | Healthcare | 1.4% | $37.5m | 3,331,465 | – | new |
| 19 | MERUS N V | 1.4% | $37.3m | 708,176 | 3% | added | |
| 20 | SLNOEUR SOLENO THERAPEUTICS INC | 1.4% | $36.1m | 430,439 | -71% | reduced | |
| 21 | CATBUSD ASTRIA THERAPEUTICS INC | 1.3% | $34.8m | 6,485,420 | 0% | held | |
| 22 | IMVT IMMUNOVANT INC | Healthcare | 1.3% | $34.2m | 2,137,890 | -25% | reduced |
| 23 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.2% | $32.1m | 255,050 | 155% | added |
| 24 | PRAX PRAXIS PRECISION MEDICINES I | Healthcare | 1.2% | $31.7m | 752,921 | -23% | reduced |
| 25 | BSX BOSTON SCIENTIFIC CORP | Healthcare | 1.1% | $30.1m | 280,000 | 115% | added |
| 26 | CAI CARIS LIFE SCIENCES INC | Healthcare | 1.1% | $29.3m | 1,098,163 | – | new |
| 27 | ISRG INTUITIVE SURGICAL INC | Healthcare | 0.9% | $24.5m | 45,119 | 11% | added |
| 28 | ADMA ADMA BIOLOGICS INC | Healthcare | 0.9% | $23.7m | 1,303,468 | -5% | reduced |
| 29 | BBNX BETA BIONICS INC | Healthcare | 0.9% | $23.2m | 1,593,608 | 0% | held |
| 30 | SYRE SPYRE THERAPEUTICS INC | 0.9% | $22.9m | 1,529,445 | -34% | reduced | |
| 31 | EOLS EVOLUS INC | Healthcare | 0.9% | $22.8m | 2,474,843 | -40% | reduced |
| 32 | CELC CELCUITY INC | Healthcare | 0.8% | $21.8m | 1,633,208 | -31% | reduced |
| 33 | DYN DYNE THERAPEUTICS INC | Healthcare | 0.8% | $21.4m | 2,247,390 | -3% | reduced |
| 34 | SION SIONNA THERAPEUTICS INC | 0.8% | $21.1m | 1,216,045 | -3% | reduced | |
| 35 | AXSM AXSOME THERAPEUTICS INC | Healthcare | 0.8% | $20.7m | 198,534 | -44% | reduced |
| 36 | RGEN REPLIGEN CORP | Healthcare | 0.8% | $20.6m | 166,000 | 28% | added |
| 37 | PODD INSULET CORP | Healthcare | 0.7% | $19.0m | 60,387 | -16% | reduced |
| 38 | OM OUTSET MED INC | 0.6% | $16.0m | 833,333 | 0% | held | |
| 39 | ZYME ZYMEWORKS INC | Healthcare | 0.6% | $16.0m | 1,275,274 | -32% | reduced |
| 40 | CTMX CYTOMX THERAPEUTICS INC | Healthcare | 0.6% | $15.9m | 6,993,646 | – | new |
| 41 | ALDX ALDEYRA THERAPEUTICS INC | Healthcare | 0.6% | $15.5m | 4,051,631 | -56% | reduced |
| 42 | CRL CHARLES RIV LABS INTL INC | Healthcare | 0.6% | $15.2m | 100,000 | – | new |
| 43 | CNTA CENTESSA PHARMACEUTICALS PLC | 0.6% | $15.1m | 1,146,935 | -62% | reduced | |
| 44 | INBX INHIBRX BIOSCIENCES INC | 0.5% | $14.0m | 977,892 | -8% | reduced | |
| 45 | ADGM ADAGIO MED HLDGS INC | 0.5% | $12.8m | 9,876,576 | 1% | added | |
| 46 | NRIX NURIX THERAPEUTICS INC | Healthcare | 0.5% | $12.5m | 1,096,985 | 269% | added |
| 47 | TVTX TRAVERE THERAPEUTICS INC | Healthcare | 0.5% | $12.3m | 834,252 | – | new |
| 48 | OBIO ORCHESTRA BIOMED HLDGS INC | 0.5% | $12.3m | 4,592,556 | 0% | held | |
| 49 | DRUG BRIGHT MINDS BIOSCIENCES INC | Healthcare | 0.4% | $11.0m | 420,690 | -5% | reduced |
| 50 | IKT INHIBIKASE THERAPEUTICS INC | 0.4% | $10.6m | 5,432,293 | -8% | reduced |
Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.